Mineralys Therapeutics Reports Q3 GAAP EPS Miss
Mineralys Therapeutics (MLYS) reported third-quarter GAAP earnings per share of -$0.64, missing analyst expectations by $0.09. The results reflect the ongoing costs associated with the company's clinical development stage. The company's liquidity position saw a slight decrease, with cash, cash equivalents, and investments totaling $624.7 million as of September 30, 2026, down from $656.6 million at the end of 2025. Management indicated that current capital levels are expected to support ongoing operations.
Tickers: $MLYS